Z-Pro-Prolinal

Summary

Z‑Pro‑Prolinal (ZPP) is a synthetic dipeptide aldehyde that acts as a potent inhibitor of prolyl oligopeptidase (POP), an enzyme that cleaves proline‑containing oligopeptides. In pre‑clinical research it has been used to probe POP function, to assess neuroprotective effects, and to explore antiparasitic activity against Trypanosoma evansi. The compound is not approved for clinical use and is employed only in laboratory settings via intracerebroventricular, intraperitoneal, or intravenous administration.

Mechanism of Action

Z‑Pro‑Prolinal binds covalently to the active‑site serine of prolyl oligopeptidase, blocking its ability to hydrolyze proline‑rich peptide substrates. Molecular‑dynamics simulations indicate that the inhibitor accesses the POP active site through a flexible loop between the β‑propeller and α/β‑hydrolase domains, inducing conformational changes that stabilize the bound state. By inhibiting POP, ZPP reduces downstream events such as glyceraldehyde‑3‑phosphate dehydrogenase (GAPDH) translocation to mitochondria/nuclei and the associated production of reactive oxygen species in certain cell types.

What the Research Shows

Early work demonstrated that Z‑Pro‑Prolinal is a nanomolar‑range inhibitor of POP in vitro and reduces enzyme activity by 50‑70% in rat brain regions after intraperitoneal dosing (1 µmol/animal). In rats, pretreatment prevented scopolamine‑induced amnesia in passive‑avoidance tests, suggesting anti‑amnesic potential. Cell‑culture studies showed that ZPP blocked GAPDH translocation and 6‑hydroxydopamine‑induced reactive oxygen species in CV1‑P fibroblasts, though similar effects were not observed in SH‑SY5Y neuroblastoma cells. Computational work identified a preferred binding pathway through a flexible inter‑domain loop of POP. A 2023 parasitology study reported modest in vitro growth inhibition of Trypanosoma evansi (IC50 ≈ 63 µM), with up‑regulation of aurora kinase gene expression, indicating limited antiparasitic activity.

Reported Benefits

Pre‑clinical data suggest Z‑Pro‑Prolinal can effectively inhibit POP at low nanomolar concentrations, leading to measurable anti‑amnesic effects in rodent behavioral assays. In fibroblast models, the compound reduces oxidative stress markers linked to neurotoxic insults, supporting its utility as a tool to explore neuroprotective pathways. Computational analyses provide insight into selective binding mechanisms that may guide design of more drug‑like POP inhibitors. Limited antiparasitic activity against Trypanosoma evansi has also been observed in vitro.

Limitations of the Evidence

Evidence for Z‑Pro‑Prolinal is confined to in vitro assays, rodent models, and computational simulations; no human studies exist. Protective effects on GAPDH translocation and ROS were cell‑type specific, absent in SH‑SY5Y neuroblastoma cells. Antiparasitic potency is modest (IC50 ≈ 63 µM) and lacks in vivo validation. The compound’s pharmacokinetic properties, brain penetration, and long‑term safety are uncharacterized, and its inhibition of other serine proteases has not been fully explored.

Safety Considerations

No adverse effects were reported in the animal or cell studies cited for Z‑Pro‑Prolinal. The anti‑amnesic study noted enzyme inhibition in multiple brain regions without reported toxicity at 1 µmol intraperitoneal dose. Cytotoxicity assessments in the Trypanosoma study focused on kinase inhibitors, not ZPP. Nonetheless, the absence of systematic safety evaluation means potential off‑target protease inhibition or metabolic liabilities remain unknown, warranting caution in further experimental use.

How It Is Administered

In research settings Z‑Pro‑Prolinal has been administered intracerebroventricularly, intraperitoneally, and intravenously to rodents. Formulations are typically aqueous solutions prepared for injection; specific excipients or concentrations are not detailed in the cited literature.

Routes of Administration

Goals & Uses

• Investigate role of prolyl endopeptidase in cognitionResearchModerate
• Neuropeptide metabolism researchNeuroscience / BiochemistryModerate
• Psychiatric disorder modelingPreclinical Disease ModelingLow
• Validate PEP as therapeutic targetResearchModerate
• Prolyl endopeptidase inhibitionEnzyme Inhibition / Pharmacological ToolHigh
• Cognitive and memory researchNeuropharmacologyModerate

Contraindications

• Human clinical useRegulatoryHigh

Adverse Effects

• Off-target protease inhibitionPharmacologicalUnknown
• Behavioral alterationsNeurological (preclinical)Unknown
• UnknownUnknownUnknown

Drug Interactions

No drug interactions recorded yet.

Population Constraints

• All human populationsGeneralAbsolute

Regulatory Status

• European UnionUnapprovedResearch chemical only; no CTA filed.
• United StatesUnapprovedResearch chemical only; no IND filed.
• United KingdomUnapprovedResearch chemical only; no clinical authorisation.

No regulatory approval in any jurisdiction. Used exclusively as a biochemical research tool. Not an approved drug or investigational medicinal product under IND/CTA.

Evidence & Sources

• Purification and characterization of a Z-pro-prolinal-insensitive Z-Gly-Pro-7-amino-4-methyl coumarin-hydrolyzing peptidase from bovine serum--a new proline-specific peptidase
  Journal ArticleLowBirney YA, O'Connor BF2001-01-01T00:00:00.000000Z
• Use of Umbrella Sampling to Calculate the Entrance/Exit Pathway for Z-Pro-Prolinal Inhibitor in Prolyl Oligopeptidase
  Journal ArticleLowSt-Pierre JF, et al.2011-01-01T00:00:00.000000Z
• In vitro and in vivo evaluation of kinase and protease inhibitors against Trypanosoma evansi
  Journal ArticleLowBhutia WD, et al.2023-01-01T00:00:00.000000Z
• A prolyl oligopeptidase inhibitor, Z-Pro-Prolinal, inhibits glyceraldehyde-3-phosphate dehydrogenase translocation and production of reactive oxygen species in CV1-P cells exposed to 6-hydroxydopamine
  Journal ArticleLowPuttonen KA, et al.2006-01-01T00:00:00.000000Z
• Identification and initial characterisation of a N-benzyloxycarbonyl-prolyl-prolinal (Z-Pro-prolinal)-insensitive 7-(N-benzyloxycarbonyl-glycyl-prolyl-amido)-4-methylcoumarin (Z-Gly-Pro-NH-Mec)-hydrolysing peptidase in bovine serum
  Journal ArticleLowCunningham DF, O'Connor B1997-01-01T00:00:00.000000Z
• Specific inhibitors for prolyl endopeptidase and their anti-amnesic effect
  Journal ArticleLowYoshimoto T, et al.1987-01-01T00:00:00.000000Z

Frequently Asked Questions